Generex Biotechnology Corporation, a leader in the area of buccal drug delivery, announced today that it has entered into contractual arrangements with Cardinal Health, Inc., the leading provider of products and services supporting the health-care industry, to manufacture clinical trial batches of Generex Oral-lyn, a proprietary oral insulin spray product.

Under the terms of the contract, Cardinal Health will formulate and fill clinical trial batches of the canisters at its manufacturing and analytical services facility in Research Triangle Park, NC. Additional terms of the agreement were not disclosed.

Ranked No. 19 on the Fortune 500, Cardinal Health manufactures or packages products for nine out of the top 10 pharmaceutical companies and most leading biotechnology companies. The company manufactures or packages more than half a billion doses of pharmaceuticals every day.

"Cardinal Health's expertise in pharmaceutical manufacturing will be of great value during the remaining trials of our Generex Oral-lyn product," said Anna Gluskin, President and CEO of Generex. "We hope to continue to utilize their proven capabilities as we move forward with the global commercialization of Generex Oral-lyn."

NEWS ARCHIVES

2008

• September
• August
• July
• June
• May
• April
• March

2007

• April
• March
• February
• January

2006

• December
• November
• October
• September
• August
• July
• June
• May
• April
• March
• February
• January

2005

• December
• November
• October
• August
• June
• April
• March
• February

2004

• December

NEWSLETTER SIGNUP